/clinical/,/clinical/cckm-tools/,/clinical/cckm-tools/content/,/clinical/cckm-tools/content/beacon-protocols/,/clinical/cckm-tools/content/beacon-protocols/supportive-care/,

/clinical/cckm-tools/content/beacon-protocols/supportive-care/name-122923-en.cckm

201711331

page

100

UWHC,UWMF,

Tools,

Clinical Hub,UW Health Clinical Tool Search,UW Health Clinical Tool Search,Beacon Protocols,Supportive Care

CSC SC Darbepoetin Weekly Ver 11-20-17 (HL 2604)

CSC SC Darbepoetin Weekly Ver 11-20-17 (HL 2604) - Clinical Hub, UW Health Clinical Tool Search, UW Health Clinical Tool Search, Beacon Protocols, Supportive Care


CSC SC DARBOPOETIN WEEKLY VER: 11-20-17 –  Properties
Cycle 1 –  11/21/2017 through 12/18/2017 (28 days), Planned
Day 1, Cycle 1 –  Planned for 11/21/2017
Pre-Labs
TRANSFERRIN
Expires: S+365
FERRITIN
Expires: S+365
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Day 8, Cycle 1 –  Planned for 11/28/2017
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Day 15, Cycle 1 –  Planned for 12/5/2017
Treatment Conditions
Treatment Condition A
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Fiona F [2462287]
11/21/2017 10:14:22 AM Page 1 of 9
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org

Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Day 22, Cycle 1 –  Planned for 12/12/2017
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Cycle 2 –  12/19/2017 through 1/15/2018 (28 days), Planned
Day 1, Cycle 2 –  Planned for 12/19/2017
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Fiona F [2462287]
11/21/2017 10:14:22 AM Page 2 of 9
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised:
 
11/2017CCKM@uwhealth.org

Day 8, Cycle 2 –  Planned for 12/26/2017
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Day 15, Cycle 2 –  Planned for 1/2/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Day 22, Cycle 2 –  Planned for 1/9/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Fiona F [2462287]
11/21/2017 10:14:22 AM Page 3 of 9
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised:
 
11/2017CCKM@uwhealth.org

Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Cycle 3 –  1/16/2018 through 2/12/2018 (28 days), Planned
Day 1, Cycle 3 –  Planned for 1/16/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Day 8, Cycle 3 –  Planned for 1/23/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Day 15, Cycle 3 –  Planned for 1/30/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Fiona F [2462287]
11/21/2017 10:14:22 AM Page 4 of 9
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised:
 
11/2017CCKM@uwhealth.org

ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Day 22, Cycle 3 –  Planned for 2/6/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Cycle 4 –  2/13/2018 through 3/12/2018 (28 days), Planned
Day 1, Cycle 4 –  Planned for 2/13/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Day 8, Cycle 4 –  Planned for 2/20/2018
Treatment Conditions
Treatment Condition A
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Fiona F [2462287]
11/21/2017 10:14:22 AM Page 5 of 9
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised:
 
11/2017CCKM@uwhealth.org

Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Day 15, Cycle 4 –  Planned for 2/27/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Day 22, Cycle 4 –  Planned for 3/6/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Cycle 5 –  3/13/2018 through 4/9/2018 (28 days), Planned
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Fiona F [2462287]
11/21/2017 10:14:22 AM Page 6 of 9
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised:
 
11/2017CCKM@uwhealth.org

Day 1, Cycle 5 –  Planned for 3/13/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Day 8, Cycle 5 –  Planned for 3/20/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Day 15, Cycle 5 –  Planned for 3/27/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Fiona F [2462287]
11/21/2017 10:14:22 AM Page 7 of 9
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised:
 
11/2017CCKM@uwhealth.org

Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Day 22, Cycle 5 –  Planned for 4/3/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Cycle 6 –  4/10/2018 through 5/7/2018 (28 days), Planned
Day 1, Cycle 6 –  Planned for 4/10/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Day 8, Cycle 6 –  Planned for 4/17/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Fiona F [2462287]
11/21/2017 10:14:22 AM Page 8 of 9
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised:
 
11/2017CCKM@uwhealth.org

ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Day 15, Cycle 6 –  Planned for 4/24/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Day 22, Cycle 6 –  Planned for 5/1/2018
Treatment Conditions
Treatment Condition A
Progress note MUST be completed for each dose administered. Select and complete one of the following in the
Progress Notes section: DARBE/EPO CSC ONC NEW, DARBE/EPO CSC ONC CONTINUING, DARBE/EPO CSC RENAL NEW
or DARBE/EPO CSC RENAL CONTINUING.
Treatment Medications
Patient Medication Guide: darbepoetin (ARANESP)
ONCE, 1 dose Starting when released
Please provide medication guide to patient
Supportive Care Medications
darbepoetin alfa (ARANESP) soln prefilled syringe
Subcutaneous, ONCE, 1 dose Starting when released
Refer to applicable Clinical Practice Guideline - Use of Darbepoetin and Epoetin in Non-Nephrology Patients or Anemia
Management in Chronic Kidney Disease.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Fiona F [2462287]
11/21/2017 10:14:22 AM Page 9 of 9
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised:
 
11/2017CCKM@uwhealth.org